COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Files An 8-K Results of Operations and Financial Condition
Item 2.02
Coherus BioSciences, Inc. Exhibit
EX-99.1 2 d771294dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Coherus BioSciences Announces Unaudited Second Quarter 2019 UDENYCA® Net Sales of $79 Million to $84 Million REDWOOD CITY,…
To view the full exhibit click here
About COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS)
Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial. Its long-acting granulocyte colony-stimulating factor (G-CSF) product candidate, CHS-1701, is a pegfilgrastim (Neulasta) biosimilar. Its clinical-stage pipeline consists of two anti-Tumor Necrosis Factors (anti-TNFs).
